Document is current
Any future updates will be listed below
-
Authors
Sasaki, Koichi https://orcid.org/0000-0001-9966-957X
Bhatia, Vipul
Asano, Yuta https://orcid.org/0000-0002-4720-2238
Bakhtiari, Jakob https://orcid.org/0009-0005-1602-5231
Kaur, Pooja
Wang, Chuyi
Matsuo, Takumi https://orcid.org/0009-0007-9876-5800
Dubois, Olivier
Chiu, Po-Chuan
Gun, Donny
Singh, Charanjit
Panagi, Ioanna
Noblecourt, Laurine
Nikolaidi, Maria https://orcid.org/0000-0001-7196-2707
Chong, Truman
Javier, Gerardo
Priceman, Saul J. https://orcid.org/0000-0002-8136-2112
Chapuis, Aude G.
Lee, John K. https://orcid.org/0000-0002-6570-2180
Ishihara, Jun https://orcid.org/0000-0002-9083-9859
- License Information
-
More Information
Article History
Received: 18 August 2024
Accepted: 13 August 2025
First Online: 23 October 2025
Competing interests
: K.S., Y.A., A.G.C., J.K.L. and J.I. are inventors on a US provisional patent application (No. 63/650,382) covering the technology described in this work. K.S. and J.I. are inventors on international patent applications (PCT/US2019/020685) covering CBD-IL-12 protein therapy. J.K.L. is an inventor on international patent applications (PCT/US2023/062428) related to STEAP1 CAR-T cells. J.K.L. holds equity in, serves on the scientific advisory board of, and receives research funding from PromiCell Therapeutics. J.K.L. is a consultant for Lyell Immunopharma. J.I. is a founder and shareholder in Arrow Immune Inc. J.I. is a scientific advisor of EsoBiotec. The remaining authors declare no competing interests.
